Investigating the role of natural antibodies and B1 cells in lung scarring diseases.
Official title: Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
Funded at University of Virginia · NIH-10996089 · Data updated 2026-11-12
This study is looking at how certain immune cells called B1 cells might help protect the lungs from damage in people with idiopathic pulmonary fibrosis (IPF), with the hope of finding new ways to treat this condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $78,222 |
| NIH project number | 5F32HL170760-02 |
| Project ID | NIH-10996089 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or other interstitial lung diseases.
✕Less likely to help
Patients with lung diseases unrelated to fibrosis or those who do not have a diagnosis of idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and currently lacking a cure. The study examines the role of B1 cells and their natural antibodies in the immune response to lung injury. By analyzing how these immune cells behave in both human patients and animal models, the research aims to uncover mechanisms that could lead to new therapeutic strategies. The approach includes assessing the frequency and function of B1 cells in the lungs and their potential protective effects against fibrosis.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve outcomes for patients with idiopathic pulmonary fibrosis.
How similar studies have gone: Previous research has shown promising results in understanding the immune mechanisms in lung diseases, suggesting potential for success in this area.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Hannan, Riley T — University of Virginia
- Study coordinator: Hannan, Riley T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.